The CADTH pan-Canadian Oncology Drug Review (pCODR) program is recruiting for membership on the pCODR Expert Review Committee. We’re seeking three oncologists, one health economist, and one pharmacist. All the details are posted here.
A document outlining the proposed project scope for CADTH’s project on Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions is now available for feedback from all interested stakeholders.
The Canadian Agency for Drugs and Technologies in Health (CADTH) has implemented a pilot process for receiving patient input submissions for therapeutic reviews from patient groups. Patient groups are invited to provide experiences and perspectives about living with the condition for which the…
In January 2012 CADTH outlined our process for undertaking Therapeutic Reviews in a Therapeutic Review Framework. Today we have updated this framework to clarify the timing and scope of these reviews, as well as the type of evidence that is considered.
These changes are outlined in more detail…
We are pleased to announce the appointment of Brent Fraser to the position of Vice-President, Pharmaceutical Reviews, effective August 4, 2015. In this role, Brent will be responsible for the CADTH Common Drug Review, the pan-Canadian Oncology Drug Review, and all other aspects of CADTH work in the…
A draft environmental scanning document on surgical interventions performed outside the hospital operating room is available for feedback from all interested stakeholders.
A draft environmental scanning document on donor human milk banks is available for feedback from all interested stakeholders.
CADTH is pleased to issue the second pan-Canadian Oncology Drug Review (pCODR) performance report.
Through the pCODR process, CADTH reviews cancer drugs and makes reimbursement recommendations to Canada's provincial and territorial public drug plans –— with the exception of Quebec –— and to…
SASKATOON, April 14, 2015 — Today, CADTH honoured two Canadian health care leaders with awards for their contributions to the growing field of health technology assessment (HTA).
Dr. Renaldo Battista, Scientific Director of Fonds de recherche du Québec – Santé, received the 2015 Dr. Jill M. Sanders…
The final science and recommendations reports for CADTH’s project on Factor V Leiden and Prothrombin Mutation Testing in Patients With Unprovoked Thromboembolism are now available.
Five emerging drugs and five new medical devices have been selected as Canada's top 10 new and emerging health technologies by the Canadian Network for Environmental Scanning in Health (CNESH) and a panel of clinical experts. The second annual Top 10 New and Emerging Health Technology Watch List…
SASKATOON, April 10, 2015 — From April 12 to 14, 2015, some of Canada’s leading experts in health technology assessment (HTA) will meet in Saskatoon for the 2015 CADTH Symposium. The conference will focus on how evidence can best be used to support informed health care decisions.
Health policy- and…